

WHITE PAPER

Comprehensive Analysis of Collagen Immunogenicity in Medical Devices

Subject: Technical Review of Immunological Risks,
Regulatory Compliance, and Advanced Mitigation
Strategies for Collagen-Based Biomaterials

ADVANCING
A HEALTHIER
TOMORROW

1 Executive Summary

Collagen remains a cornerstone of regenerative medicine and implantable devices because it is mechanically useful, biologically familiar to host cells, and amenable to remodelling in vivo. However, collagen-based devices are not immunologically uniform. Their immune risk is best understood as a product-specific variable depending on residual glycans, extracellular matrix (ECM) proteins, residual DNA, cell remnants, and the structural integrity of the collagen after processing.

A practical hierarchy for immunogenicity has emerged, placing **alpha-Gal** as the highest priority xenogeneic determinant, followed by **non-Gal ECM antigens**, and finally **telopeptide-bearing fibrillar collagen**. While clinical evidence suggests hypersensitivity reactions are rare—occurring in approximately 1–3% of dermal implant recipients—they remain a significant concern for long-term device safety. This paper reviews the molecular mechanisms, clinical evidence, and regulatory frameworks governing these materials.

2 The Immunogenic Hierarchy and Determinants

2.1 The Priority of alpha-Gal

Among candidate xenogeneic determinants, the carbohydrate alpha-Gal remains the most important and scientifically supported risk factor. Humans and Old-World primates have lost the ability to synthesize this epitope and have developed natural anti-Gal antibodies.



Clinical Relevance

Pre-existing antibodies can lead to chronic inflammation, degeneration risk, and potential IgE-mediated relevance in Alpha-Gal Syndrome (AGS).



Decellularization Limitations

Standard decellularization processes cannot eliminate alpha-Gal from the extracellular matrix.



Long-term Impacts

For long-term implants like bioprosthetic heart valves, anti-alpha-Gal IgG is common and may lead to accelerated calcification.

2.2 Telopeptides and Atelocollagen

Type I collagen contains non-helical N- and C-terminal regions known as telopeptides, which are less conserved across species than the triple-helical core.



Antigenic Sites

Telopeptides harbour many of the protein's primary antigenic sites; their removal reduces but does not eliminate immunogenicity.



Atelocollagen

Produced via pepsin treatment to remove telopeptides, atelocollagen is the lowest-risk collagen format but is not immunologically inert.



Mechanical Trade-off

Telopeptide burden affects both the immunogenicity and the mechanical properties of the device.

2.3 Non-Gal ECM Antigens and Minor Proteins

Even after donor cells are removed, minor matrix proteins can remain immunogenic. Proteomic characterization is prioritized in ECM devices to identify these residual antigens.




Figure 1. Common post-decellularization modifications to address the immunogenicity of dECM scaffolds.

Selective antigen removal techniques rely on enzymatic treatment to specifically remove antigens (i.e., α-gal, Neu5Gc, and Sda epitopes). **B** Crosslinking may reduce the immunogenicity of dECM by masking exposed antigenic sites. **C** Solubilization removes various protein antigens (hydrophobic and hydrophilic antigens) according to their common physiochemical properties. **D** Terminal sterilization eliminates pathogen-related immunogenicity of viruses and bacteria in the dECM scaffolds

From: Kasravi, Mohammadreza, et al. "Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine." *Biomaterials research* 27.1 (2023): 10

3 Mechanisms of Immune Activation

3.1 Innate Immunity and DAMPs

Collagen implants can trigger innate immunity via "Danger-Associated Molecular Patterns" (DAMPs) arising from collagen fragments, denatured protein, or residual DNA.



Pattern Recognition

TLRs and NLRs on macrophages and dendritic cells bind these DAMPs, triggering inflammation.



Host Protein Adsorption

Proteins such as fibrinogen adsorbed onto the implant surface can activate innate cells.

3.2 Decellularization-Induced Damage

The process of decellularization itself can alter the ECM and affect immunogenicity by exposing immunogenic particles or depleting immunomodulatory molecules.



Hyaluronic Acid (HA) Fragmentation

Decellularization can break down High Molecular Weight Hyaluronic Acid (HMWHA), which normally induces a regulatory phenotype in T cells and suppresses humoral immunity.



LMWHA Effects

The resulting Low Molecular Weight Hyaluronic Acid (LMWHA) interacts with toll-like receptors to invoke inflammatory responses, including leukocyte chemotaxis and M1 macrophage polarization.



Cryptic Antigens

Collagen denaturation during processing may expose cryptic antigenic sites that trigger antibody production.



Elastin Release

Damaged elastin releases particles that provoke monocyte chemotaxis and antibody-mediated immune responses.

3.3 Adaptive Immunity



Antibody Production

Humans often have natural antibodies to animal collagens due to previous exposure via diet, vaccines, or tick bites.



T-Cell Responses

While rare, T-cell mediated responses such as Th2 allergy to collagen are possible.

4 Clinical Evidence by Device Class

The clinical concern for collagen immunogenicity is highly dependent on the implantation context.

4.1 Resorbable Membranes and Fillers



Dermal Fillers

Bovine collagen injections historically showed allergy in ~1–3% of patients. Newer crosslinked porcine fillers report similar rates of ~0.8%–1.3%.



Membranes

In resorbable collagen membranes, the primary concerns are local chronic M1 inflammatory responses and altered degradation behaviour.



Wound Dressings

These generally have excellent safety records, with reports of contact allergy (Type IV) being extremely rare.

4.2 Surgical Scaffolds and Long-term Implants



Hernia Meshes (SIS)

Porcine small intestinal submucosa (SIS) meshes can provoke higher early immune reactivity than synthetic meshes, often inducing IgG anti-alpha-Gal and transient inflammation.



Cardiovascular Implants

Long-term implanted ECM devices, such as heart valves, face a demanding environment involving chronic inflammation and calcification. Failure of tissue-engineered heart valves has been documented in paediatric patients due to early immune-mediated failure.



Bone Grafts

Bovine collagen bone grafts show minimal sensitization, with one study reporting only 0.33% of patients developing new IgE allergies.

5. Regulatory Guidance and Standards

5.1 ISO 10993 Series



Risk Management

Part 1 outlines the general framework for biological evaluation.



Testing

Part 10 covers sensitization, while Part 23 focuses on irritation.



Immunotoxicity

Part 20 suggests additional testing, such as lymphocyte proliferation, if standard assays are insufficient.

5.2 ISO 22442 (Animal Tissues)



This standard defines requirements for sourcing animal tissues to minimize risks associated with prions and zoonoses, which significantly influences collagen sourcing documentation.

5.3 FDA and ASTM Guidance



ASTM F2212-25

Provides characterization criteria for Type I collagen as an implant starting material.



FDA Recommendations

Manufacturers must demonstrate pathogen inactivation, material stability, and immune reaction testing if novel components are utilized.

6. Manufacturing and Mitigation Strategies

6.1 Mitigation Techniques



Selective Antigen Removal

Enzymatic treatments specifically target antigens like alpha-Gal, Neu5Gc, and Sda epitopes.



Crosslinking

Chemical agents (e.g., glutaraldehyde) reduce immunogenicity by masking exposed antigenic sites. However, toxic residues must be quenched (e.g., with glycine, glutamic acid or glutathione) to prevent inflammation.

6.2 Source Selection

The choice of source is a primary risk management decision.



Solubilization

This process removes protein antigens based on their physiochemical properties.



Decellularization

Standard goals include <50 ng dsDNA per mg of collagen and no visible nuclei to minimize DAMP-related risks.



Recombinant Human Collagen (rHC)

Produced in yeast or plants, rHC matches endogenous human proteins and has been shown to elicit no new immune activation in animal models, although post-translational modification remains problematic.



Genetic Engineering

Using alpha-Gal knockout pigs (GGTA1/beta4GalNT2/CMAH deletion) can significantly reduce the immunoreactivity of bioprosthetic tissues.

7. Preclinical and Clinical Testing Pathway

A comprehensive testing strategy is required for regulatory approval:



Material Characterization

Defining extraction state and degree of pepsinization.



In Vitro Testing

Cytotoxicity (L929), cytokine release (TNF-alpha, IL-1beta), and complement activation (C3a/C5a).



Animal Sensitization

Guinea Pig Maximization Test or Local Lymph Node Assay (LLNA).



Irritation

Rabbit intracutaneous tests to check for erythema and oedema.



Implantation Studies

Rodent models to observe chronic inflammation and foreign-body granulomas.



Clinical Evaluation

Monitoring for adverse events, α -Gal sensitivity, and post-market surveillance.

8. Conclusion

Successful device design is not simply the achievement of acellularity. It is the controlled engineering of a matrix that has lost its most important xenogeneic triggers—specifically alpha-Gal and telopeptides—while retaining the structural features required for constructive host integration. Product-specific characterization is more informative for safety than species labels alone.

9. References

1. Lynn AK, Yannas IV, Bonfield W. Antigenicity and immunogenicity of collagen. *J Biomed Mater Res B Appl Biomater*. 2004;71(2):343-54.
2. Charriere G, Bejot M, Schnitzler L, Ville G, Hartmann DJ. Reactions to a bovine collagen implant. *J Am Acad Dermatol*. 1989;21(6):1203-8.
3. Platts-Mills TAE, Li RC, Keshavarz B, Smith AR, Wilson JM. Diagnosis and management of patients with the alpha-Gal syndrome. *J Allergy Clin Immunol Pract*. 2020;8(1):15-23.e1.
4. Tai A, Choi J, Kim J, Cho Y, Choi H, Ku Y, et al. Systematic evaluation of three porcine-derived collagen membranes for guided bone regeneration. *J Periodontal Implant Sci*. 2023;53(3):181-96.
5. Human P, Zilla P. Residual bioprosthetic valve immunogenicity: forgotten, not lost. *Front Cardiovasc Med*. 2022;8:760635.
6. Holmes R, Yang X, Li W, Hilder EF, Truong VK, Crawford RJ, et al. Influence of telopeptides on the structural and physical properties of polymeric and monomeric acid-soluble type I collagen. *Mater Sci Eng C Mater Biol Appl*. 2017;77:823-7.
7. Al-Maawi S, Orlowska A, Sader R, James Kirkpatrick C, Ghanaati S. In vivo implantation of a bovine-derived collagen membrane leads to changes in the physiological cellular pattern of wound healing. *Front Bioeng Biotechnol*. 2018;6:104.
8. Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U, et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. *Eur J Cardiothorac Surg*. 2003;23(6):1002-6.
9. Kuravi KV, Sorrells LT, Nellis JR, Rahman F, Walters AH, Matheny RG, et al. Allergic response to medical products in patients with alpha-gal syndrome. *J Thorac Cardiovasc Surg*. 2022;164(6):e411-e424.
10. Zhang R, Wang Y, Chen L, Wang R, Li C, Li Y, et al. Reducing immunoreactivity of porcine bioprosthetic heart valves by genetically deleting three major glycan antigens. *Acta Biomater*. 2018;72:196-205.
11. Kasravi M, et al. Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine. *Biomaterials research* 2023;27.1:10.